Feature | May 15, 2012

The Offbeat: Saving Heart Attack Victims With Snake Venom

Peptide in green mamba snake venom may preserve cardiac and renal function following cardiac events

Nile Therapeutics is developing a peptide derived from the venom of the green mamba snake as a 90-day, out-patient treatment to prevent hospital readmissions following acute decompensated heart failure events.

 

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), recently awarded a $2.5 million grant to Mayo Clinic’s Cardiorenal Research Laboratory to see if snake venom can improve outcomes of heart attack and heart failure patients.

The innovative research project, “Cardiovascular Peptides and Myocardial Infarction,” seeks to further understand the potential of a novel, engineered guanylyl cyclase (GC) activator, cenderitide, to reduce the level of cardiac and renal injury following a myocardial infarction, or heart attack. Researchers will try to determine whether the therapy could help prevent deterioration of cardiac and renal function following a heart attack, and potentially reduce further progression of  heart failure in patients. 

Mayo researchers invented cenderitide to activate two different subtypes of GC receptors, which uniquely differentiates cenderitide from other GC stimulating peptides. Cenderitide, a designer peptide derived from the venom of the green mamba snake, may aid in the preservation of cardiac and renal function following serious cardiovascular events, such as heart attack and acute decompensated heart failure. 

At the annual meeting of the American Heart Association in November 2011, Fernando Martin, M.D., a research fellow in the Cardiorenal Research Laboratory at Mayo Clinic, presented key research data demonstrating the ability of cenderitide to prevent the death of heart cells. 

The NHLBI grant will support basic research in the laboratory and a small proof-of-concept clinical study. Mayo plans to enroll 60 patients into the study at Mayo Clinic sites in Rochester, Minn., and Jacksonville, Fla. The endpoints of the study include safety, 30-day cardiac function, circulating hormones levels and other cardiorenal biomarkers. To learn more about the clinical study, physicians can call 507.284.4838. 

Mayo licensed cenderitide to Nile Therapeutics Inc., a biopharmaceutical company based in California. Nile is currently developing the peptide as a 90-day, outpatient treatment to prevent hospital readmissions following acute decompensated heart failure events in a study which has received a fast track investigational new drug approval from the U.S. Food and Drug Administration.

Related Content

Sponsored Content | Videos | Robotic Systems| November 22, 2016
Corindus Vascular Robotics received U.S.
Sponsored Content | Videos | TCT| November 18, 2016
DAIC Editor Dave Fornell takes a video tour of some of the most innovative new interventional cardiology technologies
Sponsored Content | Videos | Guidewires| November 18, 2016
A discussion with guidewire expert Dimitri Karmpaliotis, M.D., Ph.D., FACC, about the basics of interventional guidew
COLOR trial, TCT, NIRS, stenting vulnerable plaques, near infrared spectroscopy

An intravascular ultrasound image (IVUS) with co-registered NIRS showing yellow for the detection of lipid rich plaque in a coronary artery. 

News | Cath Lab| November 07, 2016
November 7, 2016 – Two-year results from the COLOR Trial, the first large-scale multicenter prospective study of its
Corindus, Corpath, robotic navigation, Robotic PCI, CorPath GRX
Technology | October 27, 2016
October 27, 2016 — Corindus Vascular Robotics Inc. announced it received 510(k) clearance from the U.S.
bioresorbable stents, bioabsorbable stents, visualizing the Absorb BVS, dissolving stent, disappearing stent on IVUS and OCT

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system

 

Feature | Stents Bioresorbable| October 20, 2016 | Dave Fornell
There has been a lot of interest in the interventional community regarding the Abbott Absorb Bioresorbable Vascular S
Terumo Finecross, guidewires, guide wires, guidewires 101, basics of guidewire technology

An illustration of Terumo's Finecross guidewire crossing a tight lesion. 

Feature | Guidewires| October 12, 2016 | Dave Fornell
While guidewires are a key tool used by
Transesophageal Echo, TEE. Interventional echocardiography, interventional echo, Philips, CX50

Transesophageal echo (TEE) has become an essential part of the new transcatheter structrual heart therapies, giving rise to a new sub-speciality of interventional echocardiography.  

Feature | Cath Lab Navigation Aids| September 21, 2016 | Dave Fornell
The rapid growth of transcatheter structural heart procedures and the need for increased use of echocardiography as a
bioresorbable stent, bioabsorbable stent, Absorb BVS, visualizing bioresorbable stents

A comparison of how the Abbott Absorb BVS appears with intravascular ultrasound (IVUS) on the left, and optical coherence tomography (OCT) of the right. The stent is difficult to visualize and sizing is critical, so both modalities can help in bioresorbable stent measurements and to confirm stent apposition. Left image from the Volcano IVUS system and the right image from St. Jude Medical's OCT system

 

Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth evolution of inter
3-D OCT

A 3-D OCT rendering of a stented vessel segment created on St. Jude Medical's Ilumien Optis OCT system. 

Feature | Angiography| July 15, 2016 | Dave Fornell
While angiographic X-ray fluoroscopy systems are the workhorse for transcatheter cardiovascular interventional proced
Overlay Init